Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
124.21
+0.48 (0.39%)
Dec 26, 2024, 10:24 AM EST - Market open
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.05B in the quarter ending September 30, 2024, with 8.52% growth. This brings the company's revenue in the last twelve months to $3.99B, up 5.23% year-over-year. In the year 2023, Jazz Pharmaceuticals had annual revenue of $3.83B with 4.78% growth.
Revenue (ttm)
$3.99B
Revenue Growth
+5.23%
P/S Ratio
1.93
Revenue / Employee
$1,425,969
Employees
2,800
Market Cap
7.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 147.66B |
Bausch + Lomb | 4.68B |
The Ensign Group | 4.11B |
Teleflex | 3.03B |
Chemed | 2.38B |
Lantheus Holdings | 1.50B |
Waystar Holding | 906.14M |
Repligen | 633.51M |
JAZZ News
- 2 days ago - Jazz Pharmaceuticals: Should Sing A Better Tune In 2025 - Seeking Alpha
- 8 days ago - Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 9 days ago - Jazz Pharmaceuticals Announces CEO Succession Plan - PRNewsWire
- 19 days ago - Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting - PRNewsWire
- 21 days ago - Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®) - PRNewsWire
- 21 days ago - Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024 - PRNewsWire
- 23 days ago - Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting - PRNewsWire
- 5 weeks ago - Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment - Reuters